Tagrisso

Tagrisso is a prescription-targeted cancer medicine used to treat certain types of non-small cell lung cancer (NSCLC) with specific genetic mutations in the epidermal growth factor receptor (EGFR) gene. It belongs to a class of medications known as tyrosine kinase inhibitors (TKIs), which block signals that promote cancer cell growth and division. Unlike traditional chemotherapy, Tagrisso focuses on cancer cells with specific mutations, helping reduce damage to healthy cells. This targeted approach may improve treatment outcomes and may reduce some side effects associated with chemotherapy.

Doctors prescribe Tagrisso tablets for patients whose tumors carry EGFR mutations, most commonly exon 19 deletions or exon 21 L858R mutations. It may also be used in patients whose tumors develop the EGFR T790M resistance mutation after earlier EGFR inhibitor therapy.

These mutations cause abnormal signaling that promotes uncontrolled cell growth in lung cancer. Tagrisso blocks these signals and helps slow or stop tumor growth. Tagrisso is now commonly used to treat EGFR-mutated lung cancer and is often prescribed as a first-line treatment or after other therapies stop working.

Tagrisso is FDA-approved to treat certain types of non-small cell lung cancer (NSCLC) in adults who have specific changes in their tumors in the EGFR gene.

• First-line treatment for metastatic NSCLC:Tagrisso may be used as a first-line treatment for patients with lung cancer that has spread to other parts of the body and has specific EGFR mutations, such as an exon 19 deletion or an exon 21 L858R mutation.
• Treatment after other EGFR therapies stop working:It may also be used in patients whose cancer has progressed after previous treatment with an EGFR tyrosine kinase inhibitor and whose tumors carry the EGFR T790M mutation.
• Adjuvant treatment after lung cancer surgery:Tagrisso tablets may be prescribed after complete surgical removal of the tumor to help reduce the risk of cancer coming back in patients with early-stage NSCLC and certain EGFR mutations.
• Treatment for locally advanced Stage III NSCLC:It can be helpful in patients with unresectable Stage III lung cancer (cancer that cannot be removed by surgery) whose disease has not worsened after chemotherapy and radiation therapy (chemoradiation).
• Combination treatment for metastatic NSCLC:Tagrisso may be used in combination with pemetrexed and platinum-based chemotherapy for certain patients with metastatic EGFR-mutated NSCLC.

Tagrisso (osimertinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) with specific EGFR gene mutations. Normally, the EGFR protein helps regulate cell growth, but mutations such as exon 19 deletions and exon 21 L858R substitutions can keep the receptor constantly active, leading to uncontrolled cancer cell growth.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that selectively blocks the abnormal EGFR protein and prevents the signals that allow cancer cells to grow and survive. It is also effective against the EGFR T790M resistance mutation, which can develop after treatment with earlier EGFR inhibitors.

In addition, Tagrisso can cross the blood–brain barrier, allowing it to reach cancer cells that have spread to the brain. By blocking abnormal EGFR signaling, Tagrisso may help slow tumor growth and control disease progression.

The dosage and administration guide for Tagrisso:

• Tagrisso should be taken exactly as prescribed by your doctor.
• Take the tablets once a day with or without food.
• Make sure you take the medicine at the same time every day.
• Do not crush or split the Tagrisso tablet. Swallow tablets whole with water.

• Difficulty Swallowing: According to the FDA, if a patient cannot swallow the tablet whole, the tablet may be dispersed in 60 mL (2 oz) of non-carbonated water. Stir until dispersed (it won’t dissolve completely), then drink immediately. Rinse the glass with another 120-240 mL of water and drink to ensure the full dosage is taken.
• NG Tube Administration: Tagrisso can be administered via a nasogastric tube using the same dispersion method above, followed by appropriate water flushes.
• Dose Adjustments for Interactions: If treatment with a strong CYP3A inducer (such as rifampin) cannot be avoided, the recommended Tagrisso dose may be increased to 160 mg once daily.

Tagrisso has both common and serious side effects. Contact your doctor immediately if you experience severe or unusual symptoms.

Before you take Tagrisso tablets, keep the following precautions in mind:

• Monitor for lung problems: Tagrisso may cause serious lung inflammation called interstitial lung disease (ILD). Contact your oncologist immediately if you develop new or worsening symptoms such as cough, shortness of breath, or fever.
• Heart monitoring may be required: This medicine can affect heart rhythm and heart function. Patients with a history of abnormal heart rhythms or heart disease should be monitored with electrocardiograms (ECGs) and heart function tests during treatment.
• Watch for eye symptoms: Tagrisso may cause keratitis. Inform your healthcare provider if you experience redness, eye pain, blurred vision, or increased sensitivity to light.
• Regular blood tests may be needed: Your doctor may check blood counts and electrolyte levels during treatment to monitor for possible changes caused by the medication.
• Pregnancy precautions: Tagrisso may harm an unborn baby. Women of reproductive potential should use effective birth control during treatment and for at least 6 weeks after the last dosage. Men with partners who may become pregnant should use contraception during treatment and for 4 months after the last dose.
• Avoid breastfeeding: Breastfeeding is not recommended during treatment with Tagrisso and for at least 2 weeks after the final dose because the medicine may pass into breast milk.
• Inform your doctor about other medications: Some medicines and supplements can interact with Tagrisso and affect its effectiveness. Always tell your healthcare professional about any over-the-counter medicines, prescription medications, or herbal supplements you are taking.
• Use only under medical supervision: Tagrisso should be used only in patients with confirmed EGFR mutations, and treatment should be administered by a healthcare professional experienced in cancer therapy.

Patients taking Tagrisso tablets should be monitored closely. The medication may cause certain serious adverse reactions. Tagrisso warnings include:

• Interstitial lung disease (ILD) or pneumonitis: Tagrisso can cause severe or life-threatening lung inflammation. Symptoms may include new or worsening shortness of breath, fever, or cough. Treatment should be permanently discontinued if interstitial lung disease is confirmed.
• QT interval prolongation: Tagrisso may prolong the QT interval, potentially leading to serious cardiac arrhythmias. Patients with a history of heart rhythm disorders, electrolyte imbalances, or those taking medications that affect the QT interval should be monitored with periodic electrocardiograms (ECGs) and electrolyte tests.
• Cardiomyopathy: Cases of decreased heart function and heart failure have been reported in patients receiving Tagrisso. Healthcare providers may monitor left ventricular ejection fraction (LVEF) in patients with cardiac risk factors.
• Keratitis and other eye disorders: Eye inflammation, including keratitis, has been observed in patients treated with Tagrisso. Patients should report symptoms such as eye pain, redness, tearing, changes in vision, or sensitivity to light.
• Embryo-fetal toxicity: Tagrisso may cause harm to an unborn baby. Women of reproductive potential should use effective contraception during treatment and for at least 6 weeks after the last dose. Male patients with female partners of reproductive potential should use contraception during treatment and for 4 months after the last dose.
• Blood and laboratory abnormalities: Treatment may alter blood counts and electrolyte levels. Regular laboratory monitoring may be required during therapy.

Tagrisso should not be taken by:

• Patients with hypersensitivity to osimertinib or its components.

If you experience a Tagrisso overdose, call the Poison Control Center at 1-800-222-1222 immediately. Seek emergency medical help if any severe symptoms occur.

If you are taking Tagrisso, follow the regimen as directed. If you miss a dose of Tagrisso, follow a simple set of instructions:

• Take it as soon as possible.
• If it is time for your next scheduled Tagrisso dose, skip the missed one.
• Do not double your Tagrisso dose, as this can lead to severe consequences.

Keep the following Tagrisso storage guidelines in mind to keep the medication in a proper condition:

• Store the medicine at room temperature (20°C-25°C or 68°F-77°F).
• Store Tagrisso in the original bottle with the desiccant to protect from moisture.
• Do not split or crush the tablets.
• Store Tagrisso in a dry place.
• Do not keep tablets in the bathroom to avoid humidity-induced degradation.
• Keep out of reach of children and pets.

Certain medications may interact with Tagrisso, particularly strong CYP3A inducers or drugs that prolong the QT interval. Consult your healthcare professional for the complete list of Tagrisso interactions.

• Acetaminophen
• Albuterol
• Amlodipine
• Aspirin
• Atorvastatin
• Benzonatate
• Carboplatin
• Dexamethasone
• Doxycycline
• Eliquis (apixaban)
• Folic acid
• Gabapentin
• Hydrochlorothiazide
• Imipramine
• Levothyroxine
• Melatonin
• Metformin
• Omeprazole
• Ondansetron

Consult your doctor before taking any of the following Tagrisso alternatives if Tagrisso is unavailable.

• Gefitinib
• Erlotinib
• Afatinib
• Dacomitinib
• Immunotherapy (in certain cases)
• Chemotherapy combinations

The choice of therapy depends on:

• Previous treatments
• Mutation type
• Cancer stage
• Overall health

How long Tagrisso is used depends on the patient’s condition, cancer stage, and treatment response.

Typical treatment durations include:

• Adjuvant therapy after surgery: Can take up to 3 years in some cases.
• Metastatic cancer treatment: Treatment may continue until disease progression.

Some patients may continue treatment for months or even years if the drug continues to control the cancer.

Tagrisso is generally an expensive targeted cancer medication. In the United States, the price of Tagrisso can vary widely, depending on dosage, pharmacy pricing, and insurance coverage. Since treatment for advanced cancer is often long-term, many patients look for ways to lower medication costs. Patients may choose to order Tagrisso online from Canada to explore potential cost savings.

Tagrisso can be costly if you purchase it from local U.S. pharmacies, especially if you don’t have insurance coverage. At Polar Bear Meds, we help you access your prescribed medications at more affordable prices by sourcing them through fully licensed Canadian and international pharmacy partners.

You can buy Tagrisso online in Canada from Polar Bear Meds and enjoy additional benefits such as:

• Competitive pricing on genuine, prescription-based Tagrisso.
• Exclusive savings opportunities, including a Tagrisso coupon code for additional discounts on your first order.
• Effortless shipping within 3-5 business days through our reliable courier partners like Xpress Post.

At Polar Bear Meds, your prescription is filled through licensed pharmacy partners to ensure authenticity and safety. If you are looking for a reliable and affordable way to buy Tagrisso online from Canada, Polar Bear Meds offers a convenient option.

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7
• https://www.drugs.com/tagrisso.html
• https://www.fda.gov/drugs/resources-information-approved-drugs/osimertinib-tagrisso
• https://medlineplus.gov/druginfo/meds/a616005.html